Aspartate Aminotransferase-to-platelet Ratio Index (APRi) as Biomarker for Liver Damage in Biliary Atresia (BA): A Meta-analysis
Topic overview
This meta-analysis evaluates the APRi score as a non-invasive alternative to liver biopsy for assessing fibrosis severity in pediatric biliary atresia patients. The study addresses gaps in standardized diagnostic criteria and examines APRi accuracy across diverse patient populations, providing evidence for clinical decision-making in this severe pediatric liver condition.
Key takeaways
- APRi is a non-invasive biomarker that may replace liver biopsy for assessing fibrosis severity in pediatric biliary atresia patients.
- Biliary atresia progresses to cirrhosis without prompt intervention, making early fibrosis assessment critical for treatment decisions.
- Standardized APRi cutoff values for pediatric BA populations are not yet established, limiting clinical implementation across diverse cohorts.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Aspartate Aminotransferase-to-platelet Ratio Index (APRi) as Biomarker for Liver Damage in Biliary Atresia (BA): A Meta-analysis. GlobalCastMD Medical Library. 2025-01-31. https://dev.library.globalcastmd.com/article/9742?via_space=staycurrentmd
Comments